FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 356:1364-1366 March 29, 2007 Number 13 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Nissen, S. E. PubMed Citation

Plasma levels of high-density lipoprotein (HDL) cholesterol are inversely related to the incidence of coronary heart disease and stroke. The lowering of low-density lipoprotein (LDL) cholesterol with statin therapy reduces the risk of atherosclerotic cardiovascular disease but only by about one third. These findings have led to the idea that raising HDL cholesterol might be a treatment for atherosclerosis. On the basis of the high-HDL phenotype of a human genetic deficiency of cholesteryl ester transfer protein (CETP),¹ a new class of drugs that inhibit CETP was developed.² Although the CETP inhibitor torcetrapib is effective at raising HDL cholesterol levels, it . . . [Full Text of this Article]

Source Information

From the Department of Medicine, Columbia University, New York.

This article (10.1056/NEJMe078029) was published at www.nejm.org on March 26, 2007.

This article has been cited by other articles:

• Seiler, S., Schlitt, A., Jiang, X.-C., Ulrich, C., Blankenberg, S., Lackner, K. J., Girndt, M., Werdan, K., Buerke, M., Fliser, D., Heine, G. H. (2008). Cholesteryl ester transfer protein activity and cardiovascular events in patients with chronic kidney disease stage V. Nephrol Dial Transplant 23: 3599-3604 [Abstract] [Full Text]  
• Su, Y. R., Blakemore, J. L., Zhang, Y., Linton, M. F., Fazio, S. (2008). Lentiviral Transduction of ApoAI Into Hematopoietic Progenitor Cells and Macrophages: Applications to Cell Therapy of Atherosclerosis. Arterioscler. Thromb. Vasc. Bio. 28: 1439-1446 [Abstract] [Full Text]  
• Thompson, A., Di Angelantonio, E., Sarwar, N., Erqou, S., Saleheen, D., Dullaart, R. P. F., Keavney, B., Ye, Z., Danesh, J. (2008). Association of Cholesteryl Ester Transfer Protein Genotypes With CETP Mass and Activity, Lipid Levels, and Coronary Risk. JAMA 299: 2777-2788 [Abstract] [Full Text]  
• Ibanez, B., Vilahur, G., Cimmino, G., Speidl, W. S., Pinero, A., Choi, B. G., Zafar, M. U., Santos-Gallego, C. G., Krause, B., Badimon, L., Fuster, V., Badimon, J. J. (2008). Rapid change in plaque size, composition, and molecular footprint after recombinant apolipoprotein A-I Milano (ETC-216) administration: magnetic resonance imaging study in an experimental model of atherosclerosis.. J Am Coll Cardiol 51: 1104-1109 [Abstract] [Full Text]  
• Lavie, C. J., Milani, R. V. (2008). Shedding light on high-density lipoprotein cholesterol: the post-ILLUMINATE era.. J Am Coll Cardiol 51: 56-58 [Full Text]  
• Zeller, M., Masson, D., Farnier, M., Lorgis, L., Deckert, V., Pais de Barros, J.-P., Desrumaux, C., Sicard, P., Grober, J., Blache, D., Gambert, P., Rochette, L., Cottin, Y., Lagrost, L. (2007). High Serum Cholesteryl Ester Transfer Rates and Small High-Density Lipoproteins Are Associated With Young Age in Patients With Acute Myocardial Infarction. J Am Coll Cardiol 50: 1948-1955 [Abstract] [Full Text]  
• Cuchel, M., Rader, D. J. (2007). Is the Cholesteryl Ester Transfer Protein Proatherogenic or Antiatherogenic in Humans?. J Am Coll Cardiol 50: 1956-1958 [Full Text]  
• Gilbert, R. E. (2007). Rosiglitazone: Opening Pandora's Black Box?. CJASN 2: 1329-1331 [Full Text]  
• Porchay-Balderelli, I., Pean, F., Bellili, N., Jaziri, R., Marre, M., Fumeron, F., for the DIABHYCAR Study Group, (2007). The CETP TaqIB Polymorphism Is Associated With the Risk of Sudden Death in Type 2 Diabetic Patients. Diabetes Care 30: 2863-2867 [Abstract] [Full Text]  
• Lindsay, A. (2007). JournalScan. Heart 93: 1008-1010 [Full Text]  
• (2007). Torcetrapib Does Not Limit Atherosclerosis Progression. Journal Watch Cardiology 2007: 2-2 [Full Text]